Nissen-Meyer R. The Scandinavian clinical trials. Experientia Suppl 1982;41:571–579.
93.
Bonadonna G, Valagussa P. Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 1985;3:259–275.
94.
Fisher B, Carbone P, Economou SG, et al. L-phenylalanine mustard in the management of primary breast cancer: a report of early findings. N Engl J Med 1975;292:117–122.
95.
Mueller CB, Lesperance ML. NSABP trials of adjuvant chemotherapy for breast cancer: a further look at the evidence. Ann Surg 1991;214:206–211.
96.
Bonadonna G, Rossi A, Valagussa P. Adjuvant CMF chemotherapy in operable breast cancer: ten years later. World J Surg 1985;9:707– 713.
97.
Tancine G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2–10.
98.
Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10–15.
99.
Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and ﬂuorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901–906.
100.
Zambetti M, Valagussa P, Bonadonna G. Adjuvant CMF in node-negative and estrogen receptor negative breast cancer: updated results. Ann Oncol 1996;7:481–485.
101.
Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and ﬂuorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483–1496.
102.
Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol 2003;21:976–983.
103.
Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide:7 year follow-up of US Oncology Research Trial 9735. J Clin Oncol 2009;27:1177– 1183.
104.
Saurel CA, Patel TA, Perez EA. Changes to adjuvant systemic therapy in breast cancer: a decade in review. Clin Breast Cancer 2010;10:196–208.
105.